Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Nov 23;22(7):1674–1686. doi: 10.1158/1078-0432.CCR-14-2890

Figure 6.

Figure 6

PLK1 inhibition leads to decreased mesenchymal NSCLC tumor growth in vivo. Mice bearing epithelial (H1975; A) or mesenchymal (Calu6; B) NSCLC tumors were given 30 mg/kg volasertib intravenously each week or a vehicle control. Tumors were measured every 3 days. Individual tumors are graphed as thin lines with markers. The mean tumor size is indicated by the thick solid line, with the standard deviation indicated in dark gray. (C) Tumors were subjected to immunohistochemical staining with Aperio digital analysis. The average percent of tumor cells positive for Ki67 (orange bars) and the average score for E-cadherin (blue bars) were calculated with error bars representing standard deviation. Open bars, volasertib. Solid bars, control. *P ≤ 0.05 compared with control (no volasertib).